{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:26:20Z","timestamp":1788279980680,"version":"build-2803163510"},"reference-count":20,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2008,7,7]],"date-time":"2008-07-07T00:00:00Z","timestamp":1215388800000},"content-version":"vor","delay-in-days":2470,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2001,10,2]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Several clinical trials have shown that pantoprazole (40\u2003mg) and omeprazole (40 or 20\u2003mg) have similar efficacy and safety in the treatment of grade II\u2013IV reflux oesophagitis (Savary\u2013Miller classification).<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim:<\/jats:title><jats:p>To compare the efficacy and safety of once\u2010daily doses of pantoprazole (20\u2003mg) and omeprazole (20\u2003mg) with respect to symptom relief and healing of patients with grade I reflux oesophagitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Patients with endoscopically established grade I reflux oesophagitis (non\u2010confluent, patchy red lesions with\/without white fibrin coating) were enrolled into this randomized, open, parallel\u2010group, multicentre study. A total of 328 patients (<jats:italic>n<\/jats:italic>=166 in the pantoprazole group, <jats:italic>n<\/jats:italic>=162 in the omeprazole group) were recruited in 23 centres. Patients received 4\u2003weeks of treatment. If the reflux oesophagitis was not completely healed, the treatment was extended to 8\u2003weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>After 2 and 4\u2003weeks of treatment with either pantoprazole or omeprazole, the rate of symptom relief was similar (70% vs. 79% and 77% vs. 84%, respectively). High healing rates were observed after 4 and 8\u2003weeks (pantoprazole: 84% and 90%, respectively; omeprazole: 89% and 95%, respectively). Both treatments were well tolerated. The most frequently reported adverse events on pantoprazole and omeprazole, respectively, were nausea (8% vs. 7%), diarrhoea (5% vs. 6%) and headache (6% vs. 3%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>After 4 and 8\u2003weeks of treatment with pantoprazole (20\u2003mg) or omeprazole (20\u2003mg), patients with mild gastro\u2010oesophageal reflux disease (grade I) showed comparably high rates of symptom relief and healing. Both treatments were safe and well tolerated.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.2001.01089.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:43:10Z","timestamp":1047354190000},"page":"1585-1591","source":"Crossref","is-referenced-by-count":24,"title":["Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis"],"prefix":"10.1111","volume":"15","author":[{"given":"K. D.","family":"Bardhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Van Rensburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"(on behalf of the investigators)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,7,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199610001-00004"},{"key":"e_1_2_6_3_2","first-page":"185","article-title":"Pharmacokinetics of pantoprazole in man","volume":"34","author":"Huber R","year":"1996","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_6_4_2","first-page":"31","article-title":"Lack of pantoprazole drug interactions in man: an updated review","volume":"34","author":"Steinijans VW","year":"1996","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_6_5_2","first-page":"601","article-title":"Efficacy of pantoprazole in reflux erosive esophagitis (EE) is dose related","volume":"59","author":"Bochenek W","year":"1998","journal-title":"Digestion"},{"key":"e_1_2_6_6_2","first-page":"F251","article-title":"Dose\u2010response of pantoprazole 20, 40 and 80 mg on 24\u2013hour intragastric pH and serum gastrin in man","volume":"34","author":"Reill L","year":"1993","journal-title":"Gut"},{"key":"e_1_2_6_7_2","first-page":"A208","article-title":"A double\u2010blind, randomized, crossover, dose\u2010response study of the effects of 10, 20, or 40 mg of oral pantoprazole taken once daily on intragastric pH in healthy adults","volume":"116","author":"Katz PO","year":"1999","journal-title":"Gastroenterology"},{"key":"e_1_2_6_8_2","unstructured":"SavaryM&MillerG.The esophagus. In: Savary M Miller G eds. Handbook and Atlas of Endoscopy. Soluthurn Switzerland: Verlag Gassmann AG 1978: 119\u2013205."},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02090077"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529709011212"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1997.tb00799.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529709011211"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1993.tb00125.x"},{"key":"e_1_2_6_14_2","unstructured":"SAS Institute Inc.SAS\/STAT\u00aeUse\u0155s Guide Version 6 4th edn. Vol. 1. Cary NC: SAS Institute Inc. 1990."},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200012020-00011"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199802000-00004"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00381.x"},{"key":"e_1_2_6_18_2","first-page":"A180","article-title":"Efficacy of pantoprazole 20 mg vs. placebo once daily in the treatment of patients with symptomatic reflux disease and endoscopically normal esophagus","volume":"116","author":"Moola SAH","year":"1999","journal-title":"Gastroenterology"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)81075-5"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70544-5"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.41.3.277"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.01089.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.01089.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2001.01089.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T10:05:43Z","timestamp":1697537143000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2001.01089.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10,2]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2001,10,2]]}},"alternative-id":["10.1046\/j.1365-2036.2001.01089.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2001.01089.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,10,2]]}}}